Alberto Martinez, President and CEO, Mundipharma International Ltd, " Our biosimilars platform is a key component of our growth strategy and today's acquisition is the obvious next step in us ensuring we remain agile and innovative in the biosimilars space. "We have successfully demonstrated our commercial excellence in biosimilars by building a market leading platform. Through our partnership with Celltrion on Remsima ® and Truxima ® we estimate savings for healthcare systems of approximately €330m 2 from launch to the end of 2017. By acquiring Cinfa Biotech we have now taken the first step in our plans to, not only expand our biosimilars footprint, but to develop future biosimilars which will continue to afford healthcare systems further savings and, in some cases, wider access for patients ."